首页 正文

Design and baseline characteristics of the ZENITH high proteinuria trial testing zibotentan/dapagliflozin efficacy in CKD

{{output}}
Background: A low dose of the selective endothelin A receptor antagonist zibotentan in combination with the sodium - glucose co-transporter 2 inhibitor (SGLT2i) dapagliflozin reduced urinary albumin-to-creatinine ratio (UACR) by ... ...